Immunome Statistics
Total Valuation
Immunome has a market cap or net worth of $575.61 million. The enterprise value is $359.66 million.
Important Dates
The last earnings date was Wednesday, March 19, 2025, after market close.
Earnings Date | Mar 19, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Immunome has 86.95 million shares outstanding. The number of shares has increased by 195.51% in one year.
Current Share Class | 86.95M |
Shares Outstanding | 86.95M |
Shares Change (YoY) | +195.51% |
Shares Change (QoQ) | +4.37% |
Owned by Insiders (%) | 3.35% |
Owned by Institutions (%) | 55.31% |
Float | 69.55M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 45.34 |
Forward PS | n/a |
PB Ratio | 2.49 |
P/TBV Ratio | 3.16 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 39.78 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.08, with a Debt / Equity ratio of 0.03.
Current Ratio | 4.08 |
Quick Ratio | 4.00 |
Debt / Equity | 0.03 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -194.63% and return on invested capital (ROIC) is -62.37%.
Return on Equity (ROE) | -194.63% |
Return on Assets (ROA) | -49.34% |
Return on Invested Capital (ROIC) | -62.37% |
Return on Capital Employed (ROCE) | -82.53% |
Revenue Per Employee | $76,619 |
Profits Per Employee | -$2.48M |
Employee Count | 118 |
Asset Turnover | 0.05 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.34% in the last 52 weeks. The beta is 1.94, so Immunome's price volatility has been higher than the market average.
Beta (5Y) | 1.94 |
52-Week Price Change | -73.34% |
50-Day Moving Average | 9.42 |
200-Day Moving Average | 12.08 |
Relative Strength Index (RSI) | 28.65 |
Average Volume (20 Days) | 1,013,495 |
Short Selling Information
The latest short interest is 9.52 million, so 10.95% of the outstanding shares have been sold short.
Short Interest | 9.52M |
Short Previous Month | 9.30M |
Short % of Shares Out | 10.95% |
Short % of Float | 13.69% |
Short Ratio (days to cover) | 13.83 |
Income Statement
In the last 12 months, Immunome had revenue of $9.04 million and -$292.96 million in losses. Loss per share was -$5.00.
Revenue | 9.04M |
Gross Profit | -120.50M |
Operating Income | -153.46M |
Pretax Income | -232.03M |
Net Income | -292.96M |
EBITDA | -151.89M |
EBIT | -153.46M |
Loss Per Share | -$5.00 |
Full Income Statement Balance Sheet
The company has $217.30 million in cash and $4.83 million in debt, giving a net cash position of $212.47 million or $2.44 per share.
Cash & Cash Equivalents | 217.30M |
Total Debt | 4.83M |
Net Cash | 212.47M |
Net Cash Per Share | $2.44 |
Equity (Book Value) | 181.17M |
Book Value Per Share | 2.81 |
Working Capital | 167.03M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$110.79 million and capital expenditures -$53.51 million, giving a free cash flow of -$164.30 million.
Operating Cash Flow | -110.79M |
Capital Expenditures | -53.51M |
Free Cash Flow | -164.30M |
FCF Per Share | -$1.89 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | -1,697.33% |
Pretax Margin | -3,240.38% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Immunome does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -195.51% |
Shareholder Yield | -195.51% |
Earnings Yield | -51.21% |
FCF Yield | -28.72% |
Analyst Forecast
The average price target for Immunome is $26.60, which is 301.81% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $26.60 |
Price Target Difference | 301.81% |
Analyst Consensus | Strong Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | 103.40% |
EPS Growth Forecast (5Y) | -27.90% |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Immunome has an Altman Z-Score of 4.82 and a Piotroski F-Score of 1.
Altman Z-Score | 4.82 |
Piotroski F-Score | 1 |